SCHEDULE 13G/A: TCG Crossover Entities and Chen Yu Disclose 0.2% Stake in Jade Biosciences, Inc.

TCG Crossover GP I, LLC, TCG Crossover Fund I, L.P., and Chen Yu have jointly filed an amendment to their Schedule 13G, reporting a beneficial ownership of 0.2% in Jade Biosciences, Inc.'s common stock.

Summary

• TCG Crossover GP I, LLC, TCG Crossover Fund I, L.P., and Chen Yu (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G regarding Jade Biosciences, Inc.
• The filing reports an aggregate beneficial ownership of 64,023 shares of Jade Biosciences, Inc. Common Stock.
• This ownership represents 0.2% of the Issuer's outstanding Common Stock, based on 32,235,926 shares outstanding as disclosed in the Issuer's Form 8-K filed on May 1, 2025.
• TCG Crossover GP I, LLC and TCG Crossover Fund I, L.P. are organized under the laws of Delaware, while Chen Yu is a citizen of the United States.
• The Reporting Persons' principal business office is located at 705 High St., Palo Alto, CA 94301.
• The Reporting Persons expressly disclaim status as a group for the purposes of this Schedule 13G.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or outlook.

Stakeholder Impact

• Shareholders: Provides transparency regarding the beneficial ownership structure of Jade Biosciences, Inc. by TCG Crossover entities and Chen Yu.

Key Dates

Keywords

Jade Biosciences, TCG Crossover, Chen Yu, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Shareholding